Posttranslational modifications of recombinant myotube-synthesized human factor IX

Blood

Volumn 97, Issue 1, 2001, Pages 130-138

  Arruda, Valder R ^b   Hagstrom, James N ^b   Deitch, Jeffrey ^b   Heiman Patterson, Terry ^b   Camire, Rodney M ^b   Chu, Kirk ^b   Fields, Paul A ^b   Herzog, Roland W ^b   Couto, Linda B ^b   Larson, Peter J ^b   High, Katherine A ^a  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 9;

ARTICLE; BLOOD CLOTTING; CARBOHYDRATE ANALYSIS; HUMAN; HUMAN TISSUE; MYOTUBE; PRIORITY JOURNAL; PROTEIN PURIFICATION; PROTEIN SYNTHESIS;

EID: 0035165638     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V97.1.130     Document Type: Article

References (60)

1. Central nervous system bleeding in hemophiliacs
2. New-variant Creutzfeldt-Jakob disease and treatment of haemophilia
3. Clinical evaluation of viral safety of coagulation factor VIII and IX concentrates
4. A multicenter study of recombinant factor VIII (recombinate): Safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A
5. Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A
6. Seroepidemiological and ecological studies of the adenovirus-associated satellite viruses
7. AIDS retrovirus antibodies in hemophiliacs treated with factor VIII or factor IX concentrates, cryoprecipitate, or fresh frozen plasma: Prevalence, sero-conversion rate, and clinical correlations
8. Recombinant factor IX
9. Haemophilia prophylaxis in young patients - A long-term follow up
10. Experience with prophylaxis in Sweden
11. A multicenter study of viral hepatitis in a United States hemophilic population
12. Prognostic factor for all-cause mortality among hemophiliacs infected with human immunodeficiency virus
13. Mortality from liver cancer and liver disease in haemophiliac men and boys in UK given blood products contaminated with hepatitis C
14. Systemic delivery of human growth hormone by injection of genetically engineered myoblast
15. Transduction with recombinant adeno-associated virus for gene therapy is limited by leading-strand synthesis
16. Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector
17. Recombinant adeno-associated virus for muscle directed gene therapy
18. High-efficiency gene transfer into skeletal muscle mediated by electric pulse
19. Long-term correction of obesity and diabetes in genetically obese mice by a single intramuscular injection of recombinant adeno-associated virus encoding mouse leptin
20. Stable delivery of physiologic levels of recombinant erythropoietin to the systemic circulation by intramuscular injection of replication-defective adenovirus
21. Adeno-associated virus vectors preferentially transduce cells in S phase
22. Use of adeno-associated virus as a general transduction vector in mammalian cells
23. Targeted integration of adeno-associated virus (AAV) into human chromosome 19
24. Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus
25. Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector
26. Molecular cloning of cDNA encoding canine factor IX
27. The molecular basis of blood coagulation
28. Posttranslational modifications required for coagulation factor secretion and function
29. AAV-mediated gene transfer of human blood coagulation factor IX into mouse liver
30. Adeno-associated virus vector can be efficiently produced without helper virus
31. 1b M-proteins damage human spinal cord neurons co-cultured with muscle
32. Successful expression of human factor IX following repeat administration of adenoviral vector in mice
33. Fluorophore-assisted carbohydrate electrophoresis in the separation, analysis, and sequencing of carbohydrates
34. Determination and occurrence of tyrosine O-sulfate in proteins
35. Identification of functional importance of tyrosine sulfate residues within recombinant factor VIII
36. Human F.IX corrects the bleeding diathesis of mice with hemophilia B
37. Monoclonal antibodies to factor IX: Characterization and use in immunoassays for factor IX
38. Characterization and novel purification of recombinant human protein C from three mammalian cell lines
39. Biochemical characterization of recombinant factor IX
40. A monoclonal antibody to factor IX that inhibits the factor VIII: Ca potentiation of factor X activation
41. Identification of O-glycosylation, sulfation and phosphorylation sites in the activation peptide of human factor IX
42. Fluorophore-assisted carbohydrate electrophoresis (FACE) for determining the nature and consistency of recombinant protein glycosylation
43. Analysis of synthesis, processing, and secretion of proteins expressed in mammalian cells
44. Assembly of aspargine-linked oligosaccharides
45. Factor IX levels in patients with hemophilia B (Christmas disease) following transfusion with concentrates of factor IX or fresh frozen plasma (FFP)
46. Preclinical studies of recombinant factor IX
47. Production of human factor IX in animals by genetically modified skin fibroblasts: Potential therapy for hemophilia B
48. Expression of human factor IX in rat capillary endothelial cells: Toward somatic gene therapy for hemophilia B
49. Expression of human factor IX in mice after injection of genetically modified myoblasts
50. Haemophilia B: Database of point mutations and short additions and deletions. 7th ed.
51. PACE/furin can process the vitamin K-dependent pro-factor IX precursor within the secretory pathway
52. γ-Carboxyglutamic acids 36 and 40 do not contribute to human factor IX function
53. Genomic sequence and transcription start site for the human gamma-glutamyl carboxylase
54. Activation of human factor IX (Christmas factor)
55. Purification and characterization of tyrosylprotein sulfotransferase
56. Existence of distinct tyrosylprotein sulfotransferase genes: Molecular characterization of tyrosylprotein sulfotransferase-2
57. Tyrosylprotein sulfotransferase: Purification and molecular cloning of an enzyme that catalyzes tyrosine O-sulfation, a common posttranslational modification of eukaryotic proteins
58. Molecular cloning and expression of human and mouse tyrosylprotein sulfotransferase-2 and a tyrosylprotein sulfotransferase homologue in Caenorhabditis elegans
59. Structural analysis of recombinant human factor IX